The therapeutic potentials of apelin in obesity-associated diseases.


Journal

Molecular and cellular endocrinology
ISSN: 1872-8057
Titre abrégé: Mol Cell Endocrinol
Pays: Ireland
ID NLM: 7500844

Informations de publication

Date de publication:
01 06 2021
Historique:
received: 01 02 2021
revised: 26 03 2021
accepted: 02 04 2021
pubmed: 11 4 2021
medline: 15 12 2021
entrez: 10 4 2021
Statut: ppublish

Résumé

Apelin, a peptide with several active isoforms ranging from 36 to 12 amino acids and its receptor APJ, a G-protein-coupled receptor, are widely distributed. However, apelin has emerged as an adipokine more than fifteen years ago, integrating the field of inter-organs interactions. The apelin/APJ system plays important roles in several physiological functions both in rodent and humans such as fluid homeostasis, cardiovascular physiology, angiogenesis, energy metabolism. Thus the apelin/APJ system has generated great interest as a potential therapeutic target in different pathologies. The present review will consider the effects of apelin in metabolic diseases such as obesity and diabetes with a focus on diabetic cardiomyopathy among the complications associated with diabetes and APJ agonists or antagonists of interest in these diseases.

Identifiants

pubmed: 33838166
pii: S0303-7207(21)00122-2
doi: 10.1016/j.mce.2021.111278
pii:
doi:

Substances chimiques

APLN protein, human 0
APLNR protein, human 0
Anti-Obesity Agents 0
Apelin 0
Apelin Receptors 0
Dipeptidyl-Peptidase IV Inhibitors 0
Hypoglycemic Agents 0
Metformin 9100L32L2N

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

111278

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

I Castan-Laurell (I)

Restore UMR1301 Inserm, 5070 CNRS, Université Paul Sabatier, France. Electronic address: isabelle.castan@inserm.fr.

C Dray (C)

Restore UMR1301 Inserm, 5070 CNRS, Université Paul Sabatier, France.

P Valet (P)

Restore UMR1301 Inserm, 5070 CNRS, Université Paul Sabatier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH